Everest Medicines Limited
Everest Medicines Limited, a biopharmaceutical company, engages in discovery, licensing, clinical development, and commercialization of therapies to address critical unmet medical needs in Greater China and other Asia Pacific markets. Its pipeline produc…
Biotechnology
CN, Shanghai [HQ]
Ratios
6 Sheets · From 2023 to 2018Configuration
Margins, Growth Rates In %
| Ratio | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Profitability | |||||||
| Gross Margin | - - | - - | - - | 57.41 | 63.69 | 72.67 | |
| Profit Margin | - - | - - | - - | -1,876,916.67 | -1,933.11 | -670.57 | |
| Operating Margin | - - | - - | - - | -1,943,096.30 | -10,945.90 | -740.67 | |
|
EPS Growth
|
- - | 80.57 | -9,689.71 | 94.80 | 76.01 | -225.30 | |
| EPS CNY | -350.00 | -68.00 | -6,657.00 | -346.00 | -83.00 | -270.00 | |
| Return on Assets (ROA) | -137.13 | -9.05 | -75.99 | -15.25 | -3.74 | -14.63 | |
| Return on Equity (ROE) | 104.65 | 22.47 | -83.06 | -17.20 | -4.37 | -17.00 | |
| Return on Invested Capital (ROIC) | 1.77 | 19.36 | -9.49 | -16.53 | -22.74 | -18.63 | |
| Solvency | |||||||
| Equity Ratio | -100 | - - | - - | - - | - - | - - | |
| Debt/Assets | 2.32 | 1.91 | 5.98 | 7.30 | 7.62 | 8.85 | |
| Debt/Equity | -1.77 | -4.73 | 6.54 | 8.23 | 8.91 | 10.28 | |
| Debt/EBITDA | 16.93 | 28.95 | 71.85 | 221.53 | -0.87 | 1.79 | |
|
Debt/Capitalization
|
-1.80 | -4.97 | 6.14 | 7.61 | 8.18 | 9.32 | |
| Long-Term Debt/Capitalization | -1.17 | -3.64 | 5.89 | 7.19 | 1.04 | 8.63 | |
| Interest Debt per Share CNY | 0.06 | 0.15 | 5.52 | 1.67 | 1.71 | 1.70 | |
| Debt Growth | - - | 143.51 | 997.50 | 8.43 | 3.85 | 1.37 | |
| Liquidity | |||||||
| Current Ratio | 131.20 | 26.03 | 2,405.60 | 994.55 | 392.42 | 835.52 | |
| Quick Ratio | 131.20 | 26.03 | 2,405.60 | 994.38 | 391.08 | 829.21 | |
| Cash Ratio | 114.74 | 21.05 | 2,397.42 | 976.84 | 56.41 | 174.28 | |
| Operating Cash Flow Ratio | - - | - - | -200 | -200 | -100 | -200 | |
| Turnover | |||||||
| Inventory Turnover | - - | - - | - - | 5.15 | 39.92 | 181.66 | |
| Receivables Turnover | - - | - - | - - | 0.11 | 0.73 | 252.58 | |
| Payables Turnover | - - | - - | - - | 0.04 | 10.44 | 70.39 | |
|
Asset Turnover
|
- - | - - | - - | - - | 0.19 | 2.18 | |
| Fixed Turnover | - - | - - | - - | 0.02 | 1.85 | 19.33 | |
| Coverage | |||||||
| Interest Coverage | -9,434.87 | -8,796.80 | -2,890.25 | -21,787.21 | -25,043.80 | -4,045.01 | |
| Asset Coverage | 400 | - - | 1,100 | 700 | 700 | 500 | |
| Cash Flow Coverage (CFGR) | -639.07 | -217.52 | -105.49 | -150.49 | -229.45 | -150.64 | |
| EBITDA Coverage | -73,000 | -11,200 | -23,500 | -20,100 | -26,400 | -3,000 | |
| Dividend Coverage | - - | - - | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | - - | - - | - - | - - | - - | - - | |
| Market Prospects | |||||||
| Dividend Yield | - - | - - | - - | - - | - - | - - | |
| Earnings Yield | -5.48 | -1.05 | -116.97 | -12.71 | -5.41 | -14.24 | |
|
Price/Earnings (P/E)
|
-1,826.44 | -9,529.21 | -85.49 | -786.97 | -1,847.14 | -702.06 | |
| Price/Earnings Growth (PEG) | - - | 118.27 | -0.01 | 8.30 | 24.30 | -3.12 | |
|
Price/Book (P/B)
|
-1,911.45 | -2,141.07 | 71.01 | 135.37 | 80.78 | 119.32 | |
| Price/Tangible Book (P/TB) | -1,911.45 | -2,141.07 | 71.01 | 135.37 | 80.78 | 119.32 | |
| Price/Sales (P/S) | - - | - - | - - | 14,770,740.08 | 35,707.22 | 4,707.80 | |
|
Price/Cash Flow (P/CF)
|
-16,932.63 | -20,795.14 | -1,029.38 | -1,092.73 | -395.21 | -770.76 | |
| Price/Free CF (P/FCF) | -5,680.77 | -10,133.70 | -489.77 | -467.61 | -287.55 | -572.74 | |
| Price/Operating CF (P/OCF) | -16,932.63 | -20,795.14 | -1,029.38 | -1,092.73 | -395.21 | -770.76 |